ATE548380T1 - Mutante des hgf-precursor-proteins und aktivierte form davon - Google Patents

Mutante des hgf-precursor-proteins und aktivierte form davon

Info

Publication number
ATE548380T1
ATE548380T1 AT07740545T AT07740545T ATE548380T1 AT E548380 T1 ATE548380 T1 AT E548380T1 AT 07740545 T AT07740545 T AT 07740545T AT 07740545 T AT07740545 T AT 07740545T AT E548380 T1 ATE548380 T1 AT E548380T1
Authority
AT
Austria
Prior art keywords
chain
hgf
precursor protein
mutant
peptide
Prior art date
Application number
AT07740545T
Other languages
English (en)
Inventor
Toshikazu Nakamura
Kunio Matsumoto
Kazuhiro Fukuta
Kiichi Adachi
Daichika Hayata
Original Assignee
Kringle Pharma Inc
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kringle Pharma Inc, Univ Osaka filed Critical Kringle Pharma Inc
Application granted granted Critical
Publication of ATE548380T1 publication Critical patent/ATE548380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
AT07740545T 2006-04-20 2007-03-30 Mutante des hgf-precursor-proteins und aktivierte form davon ATE548380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006116498 2006-04-20
PCT/JP2007/057109 WO2007122975A1 (ja) 2006-04-20 2007-03-30 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質

Publications (1)

Publication Number Publication Date
ATE548380T1 true ATE548380T1 (de) 2012-03-15

Family

ID=38624883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07740545T ATE548380T1 (de) 2006-04-20 2007-03-30 Mutante des hgf-precursor-proteins und aktivierte form davon

Country Status (6)

Country Link
US (2) US8003607B2 (de)
EP (1) EP2014676B1 (de)
JP (1) JP5093783B2 (de)
AT (1) ATE548380T1 (de)
CA (1) CA2649800C (de)
WO (1) WO2007122975A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
JP6294221B2 (ja) 2011-03-31 2018-03-14 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
TR201908872T4 (tr) 2012-01-09 2019-07-22 Adc Therapeutics Sa Üçlü negatif meme kanserini tedavi etmek için ajanlar.
JP6568846B2 (ja) 2014-04-28 2019-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
EP3347034B1 (de) 2015-09-11 2024-05-29 The Schepens Eye Research Institute, Inc. Eine hepatozyten-wachstumsfaktor-rezeptor (hgfr)-bindende zusammensetzung zur verwendung in einem verfahren zur behandlung von hornhauttrübung oder -vernarbung
RU2747977C2 (ru) 2016-03-17 2021-05-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения активного фактора роста гепатоцитов (hgf)
EP4574211A3 (de) * 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Zusammensetzungen von wachstumsfaktor zur behandlung von augenerkrankungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JP2824434B2 (ja) 1989-11-28 1998-11-11 財団法人化学及血清療法研究所 新規発現ベクター
JP2784455B2 (ja) 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP3082171B2 (ja) 1990-06-11 2000-08-28 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
JP2750372B2 (ja) 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
PT98805B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
JP3200609B2 (ja) 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JP3030386B2 (ja) 1991-05-15 2000-04-10 敏一 中村 抗ガン剤
DE69230879T2 (de) 1991-07-26 2000-08-03 Toray Industries, Inc. Verwendung von Hepatocyten-Wachstumsfaktoren zur Herstellung eines Vermehrungssystems für Hematopoietische Stammzellen
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
JPH05213721A (ja) 1992-02-05 1993-08-24 Sansho Seiyaku Co Ltd 毛髪用外用剤
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
JP3619526B2 (ja) 1992-07-16 2005-02-09 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする肝臓疾患治療剤
JPH0656692A (ja) 1992-08-10 1994-03-01 Snow Brand Milk Prod Co Ltd Ｔｃｆ−ｉｉを有効成分とする創傷治療剤
JP3380573B2 (ja) 1992-07-16 2003-02-24 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
JP3622015B2 (ja) 1992-10-08 2005-02-23 敏一 中村 肺傷害治療剤
JPH0741429A (ja) 1993-07-30 1995-02-10 Mitsubishi Chem Corp 神経障害改善薬
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
US7351540B1 (en) * 2000-03-17 2008-04-01 Merck Patent Gmbh Protein isolation and analysis
US20030124653A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Method of producing glycoproteins having reduced complex carbohydrates in mammalian cells
AU2003277283A1 (en) 2002-10-07 2004-05-04 Genentech, Inc. Hepatocyte growth factor variants
JP2005046030A (ja) * 2003-07-31 2005-02-24 Toyobo Co Ltd Ｉ分岐形成β１，６−Ｎ−アセチルグルコサミニルトランスフェラーゼ活性を有する融合タンパク質及びその製造方法

Also Published As

Publication number Publication date
EP2014676A4 (de) 2009-06-03
US8003607B2 (en) 2011-08-23
US20110269944A1 (en) 2011-11-03
US20090209463A1 (en) 2009-08-20
US8278270B2 (en) 2012-10-02
EP2014676B1 (de) 2012-03-07
WO2007122975A1 (ja) 2007-11-01
EP2014676A1 (de) 2009-01-14
JP5093783B2 (ja) 2012-12-12
CA2649800C (en) 2016-09-20
JPWO2007122975A1 (ja) 2009-09-03
CA2649800A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
CY1109779T1 (el) Αναστολεις της hcv ns-3 πρωτεασης σερινης
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
ATE400647T1 (de) C-terminale modifikation von polypeptiden
BRPI0510063B8 (pt) plasmina recombinante modificada, polinucleotídeo codificando a mesma, vetor de expressão e micro-organismo transgênico
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
ATE495247T1 (de) Chromoprotein und fluoroproteine
CY1111630T1 (el) Παραγωγα κυτοκινων
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
GB2446550A (en) Methods for production of recombinant alpha1-antitrypsin
TW200604207A (en) A superantigen fusion protein and the use thereof
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
ATE459650T1 (de) KOMPLEMENTÄRE PEPTIDE FÜR ß-AMYLOID 29-42-PEPTID
DE602006017806D1 (de) Behandlung von neurodegeneration
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
ZA200507966B (en) A method for oxygen regulated production of recombinant staphylokinase